Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia

Trial Profile

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs CYD TDV (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Dengue; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 03 Apr 2018 Planned End Date changed from 14 Feb 2019 to 1 Aug 2019.
    • 03 Apr 2018 Planned primary completion date changed from 14 Feb 2019 to 1 Dec 2018.
    • 28 Jun 2017 Planned End Date changed from 1 Oct 2018 to 14 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top